Compass Planning Associates Inc Invests $140,000 in Pfizer Inc. (NYSE:PFE)

Compass Planning Associates Inc bought a new stake in Pfizer Inc. (NYSE:PFE) during the fourth quarter, Holdings Channel.com reports. The fund bought 5,278 shares of the biopharmaceutical company’s stock, valued at approximately $140,000.

Other institutional investors also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC acquired a new stake in Pfizer during the fourth quarter worth about $26,000. Gladius Capital Management LP grew its holdings in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares in the last quarter. Teachers Insurance & Annuity Association of America bought a new stake in shares of Pfizer during the third quarter valued at approximately $35,000. Joseph Group Capital Management raised its stake in shares of Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 771 shares in the last quarter. Finally, Sierra Ocean LLC bought a new position in Pfizer in the fourth quarter worth $34,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $25.86 on Friday. The business has a fifty day moving average of $26.28 and a 200-day moving average of $27.44. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The firm has a market cap of $146.52 billion, a PE ratio of 18.34, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the company posted $0.10 EPS. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.65%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Insider Activity

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Citigroup lowered their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Wolfe Research began coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Guggenheim reiterated a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. Finally, Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.